Literature DB >> 11568515

Abdominal migraine in children with neurofibromatosis type 1: a case series and review of gastrointestinal involvement in NF1.

R Heuschkel1, S Kim, B Korf, G Schneider, A Bousvaros.   

Abstract

BACKGROUND: Symptomatic involvement of the gastrointestinal tract in children with neurofibromatosis type 1 (NF1) is rare. Most reported complications in adults are caused by the presence of neurofibromas in the stomach, small bowel, or mesentery. In contrast, abdominal pain in children with NF1 may be the result of nonanatomic causes, such as migraine. There are no previous reports of an association between abdominal migraine and NF1.
METHODS: Children with abdominal migraine were identified from a group of children with NF1, all of whom had been followed up for a minimum of 3 years. Medical records of cases were reviewed independently by two authors. MEDLINE was searched via PubMed for all reports of children with NF1 and any associated gastrointestinal involvement.
RESULTS: Six children with NF1 and intermittent, episodic, severe abdominal pain are reported. Investigations for obstructive or inflammatory causes of abdominal pain were negative. All patients had previously been diagnosed with migraine headaches by a neurologist. In five of the six patients, propranolol (10-15 mg three times daily) resulted in relief of their abdominal pain within days of starting therapy. Our review identified 24 children in the medical literature with gastrointestinal complications of NF1, mostly secondary to visceral neurofibromas. In almost all of these cases, clinical examination and simple radiologic investigations led to the definitive diagnosis. There were no reports of abdominal migraine complicating NF1.
CONCLUSIONS: Abdominal pain secondary to migraine is an unrecognized cause of abdominal pain in children with NF1 and may be more common than anatomic causes of abdominal pain in children with NF1. In children with NF1 and severe recurrent abdominal pain in whom an evaluation for anatomic lesions is negative, a trial of migraine therapy may be indicated.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11568515     DOI: 10.1097/00005176-200108000-00010

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  7 in total

1.  Zollinger-Ellison syndrome associated with neurofibromatosis type 1: a case report.

Authors:  Wan-Sik Lee; Yang-Seok Koh; Jung-Chul Kim; Chang-Hwan Park; Young-Eun Joo; Hyun-Soo Kim; Chol-Kyoon Cho; Sung-Kyu Choi; Jong-Sun Rew; Sei-Jong Kim
Journal:  BMC Cancer       Date:  2005-07-21       Impact factor: 4.430

Review 2.  Towards a neurobiological understanding of pain in neurofibromatosis type 1: mechanisms and implications for treatment.

Authors:  Shreya S Bellampalli; Rajesh Khanna
Journal:  Pain       Date:  2019-05       Impact factor: 6.961

3.  Nutraceuticals safety and efficacy in migraine without aura in a population of children affected by neurofibromatosis type I.

Authors:  Marco Carotenuto; Maria Esposito
Journal:  Neurol Sci       Date:  2013-03-27       Impact factor: 3.307

Review 4.  Syndrome-Associated Tumors by Organ System.

Authors:  Raul S Gonzalez; Nicole D Riddle
Journal:  J Pediatr Genet       Date:  2016-03-09

Review 5.  Gastrointestinal manifestations of neurofibromatosis type 1 (Recklinghausen's disease): clinicopathological spectrum with pathogenetic considerations.

Authors:  Abbas Agaimy; Nikolaos Vassos; Roland S Croner
Journal:  Int J Clin Exp Pathol       Date:  2012-10-20

6.  Constipation in adults with neurofibromatosis type 1.

Authors:  Cecilie Ejerskov; Klaus Krogh; John R Ostergaard; Janne L Fassov; Annette Haagerup
Journal:  Orphanet J Rare Dis       Date:  2017-08-16       Impact factor: 4.123

7.  Intraductal papillary bile duct adenocarcinoma and gastrointestinal stromal tumor in a case of neurofibromatosis type 1.

Authors:  Jung Min Lee; Jae Min Lee; Jong Jin Hyun; Hyuk Soon Choi; Eun Sun Kim; Bora Keum; Yoon Tae Jeen; Hoon Jai Chun; Hong Sik Lee; Chang Duck Kim; Dong Sik Kim; Joo Young Kim
Journal:  World J Gastroenterol       Date:  2018-01-28       Impact factor: 5.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.